What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? What are some of the strategies that have worked for practices using similar payment models? These were some of the questions discussed at the Payer Exchange Summit V.
What are some of the challenges that clinical practices will face as they implement the Medicare Oncology Care Model (OCM)? What are some of the strategies that have worked for practices using similar payment models? How does The Center for Medicare & Medicaid Innovation (CMMI), also known as the Innovation Center, hope to work with oncologists for the success of the OCM? These were some of the questions that were discussed at the Payer Exchange Summit V, sponsored by the Community Oncology Alliance (COA), held October 24-25, 2016, in Tyson’s Corner, Virginia.
Experts on the panel included Jeffrey Patton, MD, chief executive officer, Tennessee Oncology; Barbara McAneny, chief executive officer, New Mexico Hematology Oncology Consultants; and Ron Klein, MD, medical officer, CMMI.
Patton provided perspective of a practice that has been 3-months into OCM. “It’s been good with respect to investing the dollars,” he said. “We used Via Oncology [clinical] pathways; nurse triage is important and we built it on a Salesforce platform. We have also developed a relationship with a palliative care company. Additionally, care coordination is the last thing with respect to OCM that we had to include as a part of our practice transformation.”
Patton said that they are focused on the top 10% of patients that may need hospitalization, who could have a major impact on care costs. He added that with 85 doctors and 32 sites of care delivery, “we try to take care of patients where they are.”
“With COME HOME our first year was spent on ramping up practices,” McAneny said. “So with OCM, practices that might already have a similar model in place might need about 6 months to gear up. We don’t yet know what the ‘targets’ will be; it’s still a blur.” She emphasized that clinical pathways are critical to adequately implement cost-saving reimbursement models. “With COME HOME, we created pathways in a collaborative way—they are a very important decision support tool. Triage pathways are important too,” she said.
Kline said he was delighted to see that oncology practices have started developing innovative ways to implement OCM, which is the objective of this pilot phase. “We have 95 practices with $6 billion in oncology spending, 3200 physicians, and 5000 providers under OCM,” Kline said adding that he hoped that through their work “we are changing oncology care in the country.”
Speaking to the significant impact of drugs on the cost of care, he said that with drugs there are 2 categories: game changing drugs are essential, but most of those are expensive. Then there are those that can be replaced by equally effective but cheaper alternatives. “It comes down to making financially stable choices on treatments,” Kline said.
He said that OCM requires physicians to include data on staging, and molecular characterization of patient tumors in the electronic health record (EHR). “We want to identify EHRs that will minimize physician burden and include them in the OCM system,” he added.
So what are some of the challenges with meeting OCM requirements, and what specific changes do clinics need to adopt to?
Kline said that staging and mutations data are not a part of the claims system. “For a better model, we need to include this information on the system.” He added that the first year of quality reporting is “pay-for-improvement, not pay-for-performance. So the statute is that you have to do this…submit the data.”
Patton expressed concern with quicker access to outcomes data. “Technology platforms like [those developed by] Flatiron Health can help us understand where we are lagging,” he said.
Addressing the importance of care coordination in improving outcomes, McAneny said, “Care coordination occurs with the simplest things in the clinic such as when a doctor speaks to a nurse about adjusting a chemotherapy dose. It’s therfore a matter of documenting these daily coordination activities.”
She told the audience that the unique experience with OCM is that she felt she was on the same page with CMS on this. “We, at our clinics, have now set up a way for patients to sit down with a mid-level provider to talk about the care plan, their goals of care, and distress issues that we can help them with.” She emphasized though that vendors need to create a platform that does not interfere with the practice workflow or make the oncologist a data-entry operator.
“The government really wants this to work…if we don’t succeed they don’t succeed,” Patton added.
Speaking to the aspect of financial risks associated with the OCM, which are 1-sided in the first 2 years and then become 2-sided, McAneny said that she has very smart data managers working for her “who used a Monte Carlo scenario.” Using this model, they tried to identify those patients whose cost of care would result in the practice paying back to Medicare. “Through the National Cancer Care Alliance, we are trying to develop a process where we share a larger group of patients and reinsure these patients to balance the associated actuarial risk,” McAneny said.
“You don’t have to assume a 2-sided risk at all during the entire 5-year period. But with 1-sided risk, you have to show savings after 2 years,” Kline told the audience.